Designing Phase 0 Cancer Clinical Trials

Anthony J. Murgo,1,2 Shivaani Kummar,2 Larry Rubinstein,1 Martin Gutierrez,2 Jerry Collins,1 Robert Kinders,3 Ralph E. Parchment,3 Jiuping Ji,3 Seth M. Steinberg,2 Sherry X. Yang,1 Melinda Hollingshead,1 Alice Chen,1 Lee Helman,2 Robert Wiltrout,2 Robert Kinders,3 Ralph E. Parchment,3 Jiuping Ji,3 Seth M. Steinberg,2 Sherry X. Yang,1 Melinda Hollingshead,1 Alice Chen,1 Lee Helman,2 Robert Wiltrout,2 Joseph E. Tomaszewski,1 and James H. Doroshow1,2

Abstract

Phase 0 trials are designed primarily to evaluate the pharmacodynamic and/or pharmacokinetic properties of selected investigational agents before initiating more traditional phase I testing. One of the major objectives of phase 0 trials is to interrogate and refine a target or biomarker assay for drug effect in human samples implementing procedures developed and validated in preclinical models. Thus, close collaboration between laboratory scientists and clinical investigators is essential to the design and conduct of phase 0 trials. Given the relatively small number of patients and tissue samples, showing a significant drug effect in phase 0 trials requires precise and reproducible assay procedures and innovative statistical methodology. Furthermore, phase 0 trials involving limited exposure of a study agent administered at low doses and/or for a short period allow them to be initiated under the Food and Drug Administration exploratory investigational new drug guidance with less preclinical toxicity data than usually required for traditional first-in-human studies. Because of the very limited drug exposure, phase 0 trials offer no chance of therapeutic benefit, which can impede patient enrollment, particularly if invasive tumor biopsies are required. The challenges to accrual are not insurmountable, however, and well-designed and executed phase 0 trials are feasible and have great potential for improving the efficiency and success of subsequent trials, particularly those evaluating molecularly targeted agents.

There is a pressing need to improve the efficiency of early cancer drug development. Despite steadily increasing investment, only about 1 in every 10 new molecular entities entering clinical development progresses to Food and Drug Administration marketing approval (1). Furthermore, the success rate is only about 5% for new anticancer agents, with the majority of them failing in late phases of clinical development, resulting in an extraordinary waste of both time and resources. Although major strides have been made in molecular biology and cancer drug discovery, the risk of clinical failure seems to be particularly high for molecularly targeted agents. The leading cause of failure tends to be lack of efficacy, due in part to the lack of predictive animal models and poorly designed clinical trials. One strategy to improve the efficiency and success of clinical drug development is to conduct phase 0 trials (2). Phase 0 trials are first-in-human studies conducted before standard phase I dose-escalation drug safety and tolerability testing. Because phase 0 trials involve lower doses of the study agent administered for a limited duration, they can be conducted under the auspices of the U.S. Food and Drug Administration exploratory investigational new drug (ExpIND) guidance. The ExpIND, described in an accompanying article (3), allows pilot clinical studies of new investigational agents to commence with less extensive preclinical toxicology data than ordinarily required for traditional phase I trials because the lower level of drug exposure confers a substantially reduced risk of toxicity. Thus, clinical evaluation can commence much earlier than possible under a traditional IND. Phase 0 trials conducted under an ExpIND can be carried out before or while the preclinical toxicology data required for a standard IND are being generated to support subsequent phase I or II trials. Phase 0 trials, however, by addressing efficacy (i.e., target effects) and/or pharmacokinetic (PK) properties early, could eliminate underperforming agents, thus avoiding wasteful expenditures on further preclinical safety testing and unnecessary scale-up drug production for larger trials. The purpose of this article is to

Authors’ Affiliations: 1Division of Cancer Treatment and Diagnosis and 2Center for Cancer Research, National Cancer Institute, Bethesda, Maryland and 3Laboratory of Human Toxicology and Pharmacology, Applied/Developmental Research Support Directorate, Science Applications International Corporation-Frederick, Inc., National Cancer Institute-Frederick, Frederick, Maryland

Received 12/13/07; revised 3/7/08; accepted 3/31/08.

Grant support: National Cancer Institute, NIH, under contract N01-CO-12400 and Division of Cancer Treatment and Diagnosis and the Center for Cancer Research of the National Cancer Institute.

Note: The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Requests for reprints: Anthony J. Murgo, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Building 31, Room 3A44, 31 Center Drive, Bethesda, MD 20892-2440. Phone: 301-496-4291; Fax: 301-496-4291; E-mail: murga@nih.gov.

© 2008 American Association for Cancer Research. doi:10.1158/1078-0432.CCR-07-4560

describe the design of phase 0 trials of anticancer agents, how they differ from traditional first-in-human trials, and their potential for significantly improving the efficiency of drug development.

**Selection of Agents for Phase 0 Trials**

The first step in contemplating a phase 0 trial is carefully considering whether an agent is an appropriate candidate or not. An ideal candidate for phase 0 testing to evaluate target or biomarker effect is one for which all of the following apply: (a) successful clinical development depends heavily on a pharmacodynamic (PD) end point, (b) the target or biomarker is credentialed (i.e., modulation of the target or biomarker in preclinical studies is associated with an antitumor effect), (c) a wide therapeutic window is expected, (d) target or biomarker modulation is anticipated at nontoxic doses and over short durations of exposure (e.g., ≤7 days), and (e) target modulation is likely to be determined with a relatively small sample size (≤10 to 15 patients). These criteria apply to novel therapeutics, imaging probes, and biomodulators. Examples of the latter include agents that interfere with DNA repair, such as inhibitors of poly(ADP-ribose) polymerase (PARP). The PARP inhibitor ABT-888 met all of the above criteria and was considered an excellent candidate for phase 0 testing. In contrast, a cytotoxic agent with a narrow therapeutic index, or a targeted agent predicted to have an effect in an unidentifiable proportion of patients (due, for example, to the absence of a credentialed biomarker), would not be an appropriate candidate for a phase 0 trial.

**Types of Phase 0 Trial Designs**

Phase 0 trial designs vary depending on the particular study objectives (Fig. 1), including one or more of those comprised in the ExpIND guidance. The main goal of phase 0 trials is to acquire, in a relatively small group of subjects receiving nontoxic doses of drug, information that would aid in the design and potential success of subsequent larger phase I to II trials. The design of phase 0 trials differs in several ways from that of traditional phase I trials (Table 1).

Phase 0 trials involve a rational transition from preclinical to clinical development (Fig. 2), which includes development of a system on which to model tissue acquisition, handling and processing, target or biomarker analytic assay development and validation, and assessment of drug effect on the target or biomarker and PK-PD relationships. The seamless transition from preclinical to clinical development is critical to the design of phase 0 trials and requires close collaboration between laboratory, drug development, and clinical scientists.

One type of phase 0 trial is designed primarily to show that the drug affects the target in human tumor and/or surrogate tissue or that a mechanism of action defined in nonclinical models can be observed in humans. Therefore, these cannot be microdose studies (3) because pharmacologically active doses are required to yield PD effects. Although the amount of preclinical toxicology data required for this type of phase 0 trial is less than that for first-in-human phase I trials (3), the extent of preclinical investigation, including in vitro and in vivo assay development, is considerable.

The target or biomarker analytic assay used in the phase 0 trial should be characterized and validated first in preclinical models, applying techniques to those models that simulate clinical procedures. Because the intent of phase 0 trials is to provide reliable PD data on which to base further clinical development decisions, such trials require integration of validated PD analytic assays that are reproducible and robust and that can be done on uniformly handled tissues (2, 4). This approach was taken in the National Cancer Institute’s recently completed phase 0 trial of the PARP inhibitor ABT-888, which to the best of our knowledge is the first, and may be the only, oncology phase 0 trial with PD as the primary end point conducted under an ExpIND (5, 6). The timing of peripheral blood mononuclear cell (PBMC) sampling and tumor biopsies, and tissue acquisition, handling, and storage procedures were extensively evaluated in preclinical models before enrolling the first patient. As the objective was to show target inhibition, patients were required to have a minimum level of target expression in tumor biopsies and PBMCs before drug administration. Therefore, to determine whether to proceed with tumor or PBMC sampling after drug administration, PD analyses of pretreatment samples were required to be done in real time, with results communicated rapidly to the clinical team so that a decision could be made to proceed with further tissue sampling. Posttreatment sampling was not done if the pretreatment values were below a threshold required to adequately detect a drug effect change from baseline. To minimize the probability of doing invasive tumor biopsies in patients receiving doses unlikely to show drug effects, biopsies should be obtained only after the plasma drug level required for target effects in animals is reached or after target modulation is observed in surrogate tissues (e.g., PBMCs or skin). In the ABT-888 trial, prespecified threshold drug plasma levels were achieved at the first dose level. This triggered the requirement for tumor biopsies at the next higher dose level, at which point marked PARP inhibition was observed. The basic design schema used in this trial followed a recently published model, which can be adapted for use in similar PD-driven trials (2). Extensive real-time interrogation of PK and PD is not commonly undertaken or consistently pursued in standard phase 1 dose-escalation trials. Correlations between target modulation in tumor biopsies versus surrogate tissues, such as PBMCs, can also be explored in phase 0 trials, potentially reducing the need for repeated tumor biopsies in future larger studies if a strong correlation is established.

A second type of phase 0 trial can be designed to evaluate clinically the properties of two or more structurally similar analogues directed at the same molecular target. In the traditional paradigm, selection of a lead candidate among related analogues for clinical development is usually based solely on results from preclinical testing. Despite advances in compound optimization, however, drug developers may still have difficulty choosing a suitable clinical candidate from several analogues with very similar preclinical biological and pharmacologic properties. Because preclinical models have limited ability to predict drug behavior in humans (7), selection based on preclinical data alone does not ensure that the most promising
analogue will be selected for clinical development. Phase 0 trials offer a platform from which to safely evaluate multiple analogues in a limited number of patients, leading to the generation of the human pharmacology data on which to base decisions about selection of the most promising candidate for further development, or the elimination of one or more analogues with unfavorable properties (e.g., lack of target inhibition, poor bioavailability, or very rapid clearance). The selection of a clinical candidate based on the results of a phase 0 trial provides a much stronger rationale for investing resources and time in conducting formal IND-directed toxicologic studies and manufacturing the quantities of clinical-grade drug product needed for larger clinical trials.

Phase 0 trials can also serve to determine a dosing regimen for a molecularly targeted agent or a biomodulator intended for use in combination with other agents, including established chemotherapeutic drugs. One advantage of the phase 0 setting is that it enables an early determination of a drug dose that could be taken into phase I combination testing. Because the optimal biological modifying dose of a targeted agent may be considerably lower than its maximally tolerated dose, the phase 0 trial could be designed to estimate a dose range and sequence of administration for subsequent combination studies based on optimal target modulation, not on maximal tolerability. This approach was successfully used in the phase 0 trial evaluating the PARP inhibitor ABT-888 (5). With as few as 14 patients, we determined a dose range and time course that produced significant inhibition of PARP, data essential to the design of several phase I trials of ABT-888 in combination with various established chemotherapeutic agents. More importantly, it was not necessary to conduct a separate single-agent phase I safety study of ABT-888, escalating to a maximum tolerated dose, before conducting several combination studies in phase I, saving as much as 1 year in clinical development time.

Lastly, phase 0 trials can be designed to develop novel imaging probes or technologies to evaluate the biodistribution, binding characteristics, and target effects of an agent in humans. Such imaging modalities using microdoses of radiopharmaceuticals can be evaluated in phase 0 trials in a limited number of patients before incorporating resource intense imaging investigations in larger trials. The ability to determine the presence of target in tumor, evaluate tumor heterogeneity, and show tumor target modulation noninvasively has fueled a growing interest in molecular imaging as a tool for anticancer drug development (8, 9). Phase 0 imaging trials could also help define patient populations in which particular therapeutic agents should be evaluated, thus enriching for likelihood of clinical benefit (10). Several pharmaceutical companies, including Johnson & Johnson, Merck, Novartis, and Pfizer, have successfully conducted trials under the ExpIND guidance to help select, or deselect, compounds for further development, with the selection based mainly on PK profiles (6).
seven ExpIND projects planned by Novartis had PK as the primary end point. Although two included PD evaluation, PD was a secondary end point (6). An accompanying article in this CCR Focus by Eliopoulos et al. (11) provides an industry perspective of conducting phase 0 trials.

Table 1. Differences between phase 0 and standard phase I trial designs

<table>
<thead>
<tr>
<th></th>
<th>Phase I trials</th>
<th>Phase 0 trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basis for starting dose</td>
<td>Results from full standard IND-directed preclinical toxicology studies</td>
<td>Results from limited preclinical toxicology studies to support ExpIND</td>
</tr>
<tr>
<td>Preclinical biomarker studies</td>
<td>Not consistently done before initiating the trial</td>
<td>Target/biomarker analytic assays are validated in preclinical models before initiating phase 0 clinical trial</td>
</tr>
<tr>
<td>Primary end point</td>
<td>Establish dose-limiting toxicities and maximum tolerated dose</td>
<td>Establish a dose range that modulates (or images) target, for use in subsequent developmental trials</td>
</tr>
<tr>
<td>Patient population</td>
<td>Advanced incurable malignancy, after failure of standard therapy</td>
<td>Advanced incurable malignancy, after failure of standard therapy, or indolent disease (e.g., CLL) not requiring immediate treatment</td>
</tr>
<tr>
<td>Washout period before and after entry</td>
<td>Usually a minimum of 4 wk</td>
<td>May be 2 wk or less 10-15</td>
</tr>
<tr>
<td>Total number of patients</td>
<td>Usually &gt;20</td>
<td>Intended to achieve desired drug exposure and/or target modulation without significant toxicity</td>
</tr>
<tr>
<td>Dose escalation</td>
<td>Guided primarily by toxicity</td>
<td>Limited dosing (e.g., 1-7 d); one cycle only</td>
</tr>
<tr>
<td>Duration of dosing</td>
<td>Repeated dosing with multiple cycles until disease progression or unacceptable toxicity</td>
<td>None</td>
</tr>
<tr>
<td>Evaluation for therapeutic benefit</td>
<td>Tumor response routinely evaluated periodically to prevent continued dosing with no potential for clinical benefit</td>
<td>PD markers are integrated in the trial to establish mechanism of action and target/biomarker analytic assay validation in patient tissue samples</td>
</tr>
<tr>
<td>Biomarker assays</td>
<td>Not consistently done because most phase I trials do not emphasize PD markers</td>
<td>At least one predrug and one postdrug administration tumor biopsy required to evaluate drug effect on target</td>
</tr>
<tr>
<td>Tumor biopsies</td>
<td>Almost always optional</td>
<td>None</td>
</tr>
<tr>
<td>PK/PD analysis</td>
<td>Samples are usually batched and analyzed at a later time point, generally after completion of the trial</td>
<td>Real time</td>
</tr>
</tbody>
</table>

Abbreviation: CLL, chronic lymphocytic leukemia.

Novel Statistical Designs for Phase 0 Trials

Phase 0 trials in cancer may be designed to determine a statistically significant, treatment-related change from baseline in a PD end point. In the ideal scenario, the PD end point will be measured both in tumor, the definitive measurement, and in a surrogate tissue, such as PBMCs. For each patient, surrogate tissue sampling may be done multiple times before treatment, to measure baseline variability within individuals, as well as multiple times after treatment, to measure the duration of target modulation. Tumor biopsies, in contrast, will often be limited to no more than one pretreatment and one posttreatment time point for ethical reasons. One of the posttreatment surrogate tissue samples should be obtained at a time roughly equal to that of the posttreatment tumor sample to enable estimation of the correlation of the two end points and to define a uniform primary posttreatment end point time. Ideally, the pretreatment sample to be used as the baseline measure should be obtained immediately before drug administration to minimize variability due to time and other factors; this may not always be feasible for the tumor biopsy. Likewise, the pretreatment surrogate tissue samples used to measure baseline variability should be over the same time period that characterizes the treatment to posttreatment primary end point time interval to reflect the same variability due to time.

Often, the PD end points will be measured for escalating dose levels. At each dose level, a statistically significant treatment-related PD effect may be determined for each individual patient and for the dose level itself (Fig. 3). For example, a minimal design (design 1 in Fig. 3) may be defined to require only three patients per dose level, as was used in our recently completed first phase 0 trial (5). For an individual patient, a treatment-related PD effect will be significant at the one-sided 0.10 significance level if the change from baseline exceeds 1.8 times the baseline SD, assuming asymptotic normality. (It may be appropriate to apply an additional minimum magnitude criterion, for example, a 50% reduction or 2-fold increase in the measure.) In many cases, it will be appropriate to transform the original measurement (using, for example, a log transform) to achieve a distribution closer to
Fig. 2. Preclinical to clinical transition in phase 0 trials and the effect of phase 0 studies on the further development of novel anticancer agents.
normality. For the surrogate tissue assay, it will be possible to use the pooled intrapatient baseline variance (determined by calculating the baseline variances for each patient, separately, and then averaging the separate variances across patients) as the baseline variance. For the tumor tissue assay, however, it will generally be necessary to use the estimated interpatient baseline variance (calculated across patients), as there will be only one pretreatment measure per patient. In either case, the baseline SD is the square root of the baseline variance. (It may also be necessary to use the larger threshold from the appropriate t distribution in place of 1.8 because of the small sample size.). Unfortunately, this will generally make determination of a statistically significant PD effect much more difficult for the assay of tumor because the interpatient variability is always greater, and often much greater, than the intrapatient variability. For example, in our ABT-888 phase 0 trial (5), 95% inhibition in PARP activity was required for the tumor end point, whereas only 55% inhibition was required for the PBMC end point, to achieve statistical significance. For brevity, we may call a statistically significant PD effect a PD response. For each dose level, for either the assay of tumor or surrogate tissue assay, we may declare a statistically significant PD effect if at least two of the three patients exhibit a PD response. For either measurement, this design yields 90% power to detect a treatment effect at a dose level that is sufficient to yield an 80% PD response rate across patients. For either measurement, the false-positive rate at the dose level is restricted to 3%, arising from the 10% false-positive rate per patient.

In many cases, a target PD response rate of 80% across patients may be inappropriately high. Instead, we may use the following design (design 2 in Fig. 3), for example, which targets a 60% PD response rate and requires only three to five patients.
per dose level. For either the tumor or surrogate tissue measurement, for an individual patient, a treatment-related PD effect will be significant at the one-sided 0.05 significance level if the change from baseline exceeds 2.3 times the baseline SD (the pooled intrapatient SD for the surrogate tissue measurement or the interpatient SD for the tumor assay). If, for either measurement, exactly one of the initial three patients treated at a dose level shows such a PD response, the dose level will be expanded to five patients. If, for both measurements, either zero or two of the three patients show a PD response, accrual to the dose level will stop. For each dose level, for either measurement, we may declare a statistically significant PD effect if at least two of the three to five patients exhibit a PD response. For either measurement, this design yields 89% power to detect a treatment effect at a dose level that is sufficient to yield a 60% PD response rate across patients. For either measurement, the false-positive rate at the dose level is restricted to 2%, arising from the 5% false-positive rate per patient.

The previously mentioned designs are meant to facilitate evaluation of the PD effect for individual subjects as well as for dose levels. They are meant primarily for phase 0 trials that show that a drug modulates a target. They can be adapted to trials, however, that evaluate two or more analogues or two or more dosing regimens. The effect of each analogue or dosing regimen can be evaluated separately, and the analogues or regimens can be compared by more standard methods across patients. In some cases, it may not be desirable to evaluate the PD effect for each subject and more standard methods may be used to compare the effects across patients for each dose level.

**Enrollment of Patients in Phase 0 Trials**

The nontherapeutic nature of phase 0 trials can impede accrual and raise ethical concerns (12–14). Although challenging, these potential barriers can be dealt with successfully or minimized by careful attention to the protocol design and informed consent process. In addition, it may be helpful to discuss the proposed trial and get the input of the institutional bioethicists in the development of the protocol design and consent document.

In designing phase 0 trials, it is important to ensure that participation will not adversely affect a patient’s eligibility to participate in subsequent therapeutic trials or adversely delay other therapy. In addition, receiving a drug as part of a phase 0 trial should not prohibit the patient from enrolling in other protocols with that agent or class of agents. In addition, given the nontherapeutic nature of such trials, and the very limited drug exposure produced, patients should not be required to wait the standard 4 weeks for “washout” before starting another trial. Shorter washout periods, such as 2 weeks or less, are probably sufficient. Keeping these points in mind when designing protocols can help overcome some of the potential barriers to enrollment.

**Limitations in the Application of Phase 0 Trials**

A fundamental goal of conducting phase 0 trials is to improve the efficiency of drug development. The recently completed phase 0 trial conducted at the National Cancer Institute shows that successful completion of these trials is feasible. There are major limitations that preclude broad application of the approach, however. As discussed previously, not all agents are appropriate for phase 0 testing. In addition, the range of resources required for the preclinical and clinical aspects of phase 0 studies, particularly those evaluating target or biomarker effects, is not available at most academic institutions. The nontherapeutic nature of the trials makes accrual difficult and third party payers are not likely to cover the associated clinical care costs. At minimum, this type of phase 0 trial requires a dedicated PD assay development laboratory and staff who have the necessary expertise in biomarker analytic assay development and validation, as well as the facilities for clinical human tissue PD and PK studies that can be done in real time. Also necessary are a well-organized system for biospecimen procurement and processing and an efficiently integrated and dedicated team of laboratory and clinical investigators with expertise in the conduct of early-phase trials.

Furthermore, the concept of conducting phase 0 trials is not widely accepted by the pharmaceutical industry because apparently only a handful of companies have acknowledged doing exploratory IND trials, and none had PD as a primary end point (6). This suggests that in general the pharmaceutical industry does not fully appreciate or is reluctant to accept the potential long-term resource savings and added value of the approach.

**Conclusion**

As discussed elsewhere in this CCR Focus section (15, 16), the execution of rationally designed phase 0 trials can greatly improve the efficiency and success of subsequent trials, particularly those for the development of molecularly targeted agents. Phase 0 trials provide an excellent opportunity to establish feasibility and further refine target or biomarker assay methodology in a limited number of human samples before initiating larger trials involving patients receiving toxic doses of the study agent (Fig. 2). Phase 0 trials do not replace phase I trials conducted under a standard IND to establish dose-limiting toxicities and define a recommended phase II dose. Nevertheless, data from phase 0 trials allow phase I studies to begin at a higher, potentially more efficacious dose, use a more limited and rationally focused schedule for PK and PD sampling, and apply a qualified PD analytic assay for assessing target modulation and reliable standard operating procedures for human tissue acquisition, handling, and processing. The design and conduct of phase 0 trials, however, require the commitment of a considerable amount and range of resources. Nevertheless, the increased effort expended to conduct rationally designed phase 0 trials should conserve resources in the long run by improving the efficiency and success of subsequent clinical development. Furthermore, in this era of molecularly targeted therapeutics, drug development in general would benefit by incorporating the principles and strategies of phase 0 trials.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.
References

Designing Phase 0 Cancer Clinical Trials


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/14/12/3675

Cited articles
This article cites 15 articles, 9 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/14/12/3675.full.html#ref-list-1

Citing articles
This article has been cited by 19 HighWire-hosted articles. Access the articles at:
/content/14/12/3675.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.